Sepsis Diagnostics Market Size, Share, Growth, and Industry Forecast 2025–2035

The Sepsis Diagnostics Market is experiencing technological transformation as healthcare providers increasingly seek faster and more reliable methods for identifying infections and guiding treatment. Molecular diagnostics, immunoassays, blood culture systems, and advanced biomarkers are becoming important components of modern sepsis management.

The market was valued at USD 0.85 billion in 2025 and is expected to reach USD 1.69 billion by 2035, expanding at a CAGR of 7.1% from 2026 to 2035, according to Market Research Future. This expansion is supported by increasing sepsis incidence, hospital-acquired infection concerns, regulatory initiatives, and the need to reduce the time between diagnosis and treatment.

Molecular diagnostics are particularly influential because they can identify pathogens and resistance markers considerably faster than conventional culture-based approaches. The technology segment accounted for approximately 36% of the Sepsis Diagnostics Market in 2025. Multiplexed molecular panels can simultaneously investigate multiple pathogens, providing clinicians with broader diagnostic information from a single sample.

Immunoassays are also gaining momentum. These technologies can support the detection and monitoring of biomarkers associated with infection and inflammation. The immunoassay segment is projected to expand at approximately 7.8% CAGR through 2035. Increasing adoption of biomarkers such as procalcitonin and presepsin is supporting their use in emergency and hospital settings.

Another significant trend is the movement toward integrated laboratory platforms. Healthcare facilities are increasingly interested in automated systems that can reduce manual processes and improve workflow efficiency. Integration of sample preparation, pathogen identification, antimicrobial susceptibility testing, and biomarker analysis can help laboratories handle growing testing requirements while addressing workforce limitations.

Point-of-care testing is creating additional opportunities. Compact diagnostic systems capable of producing results close to the patient can be particularly valuable in emergency departments and settings where centralized laboratory infrastructure is limited. Faster access to diagnostic information can support timely clinical decision-making.

Artificial intelligence is also expected to influence future diagnostic workflows. AI systems can analyze clinical and laboratory information to identify patterns associated with sepsis risk. When combined with laboratory testing, predictive analytics could help clinicians prioritize patients who require immediate assessment.

With technological development continuing across molecular diagnostics, immunoassays, automation, and AI-enabled systems, the Sepsis Diagnostics Market is expected to evolve toward faster, more integrated, and increasingly decentralized testing solutions through 2035.